Control MDT Zero 3-month 6-month 12-month Zero 3-month 6-month 12-month RBC (×106/ml) M 5.5 ± 0.6 5.2 ± 0.6 5.5 ± 0.7 5.4 ± 0.7 5.5 ± 0.7 4.5 ± 0.6* 4.8 ± 0.7* 4.3 ± 0.6* F 4.7 ± 0.5 4.6 ± 0.5 4.9 ± 0.5 4.8 ± 0.5 4.9 ± 0.5 4.3 ± 0.5* 3.9 ± 0.4* 3.8 ± 0.5* PCV (%) M 45.8 ± 3.5 43.6 ± 5.2 45.3 ± 4.8 46.1 ± 4.7 45.8 ± 3.7 39.8 ± 4.1* 37.4 ± 3.8* 35.3 ± 4.1* F 42.5 ± 3.6 39.7 ± 4.3 41.8 ± 3.7 42.3 ± 4.6 41.8 ± 3.4 36.9 ± 4.1* 34.5 ± 3.5* 32.3 ± 3.5* Hb (g%) M 15.5 ± 1.1 14.7 ± 1.5 15.5 ± 1.7 15.5 ± 1.7 15.5 ± 1.2 13.1 ± 1.4* 11.5 ± 1.3* 10.9 ± 1.1* F 13.7 ± 1.1 12.4 ± 1.2 13.5 ± 1.4 13.3 ± 1.4 13.4 ± 1.13 11.3 ± 1.2* 10.2 ± 1.1* 9.5 ± 1.0* MCH (pg) M 30.6 ± 1.9 30.2 ± 2.8 30.7 ± 2.5 31.0 ± 3 30.6 ± 2.0 29.6 ± 2.5* 28.2 ± 2.4* 28.1 ± 2.6* F 30.6 ± 2.3 29.9 ± 2.5 30.3 ± 2.9 30.2 ± 2.6 30.3 ± 2.0 28.5 ± 2.8* 27.4 ± 2.7* 27.6 ± 2.8* MCHC (g%) M 32.7 ± 1.5 32.1 ± 2.1 32.0 ± 2.4 32.4 ± 2.2 32.6 ± 1.3 30.8 ± 2.1* 30.0 ± 1.9* 30.5 ± 2.4* F 32.5 ± 1.4 31.9 ± 2.7 32.6 ± 2.3 32.4 ± 2.4 32.7 ± 1.5 31.6 ± 2.2* 29.9 ± 2.0* 30.3 ± 2.3* *Significantly different from corresponding control group (p<0.05)

Table 3: Temporal hematological findings in Saudi patients under MDT protocol for one year.

Goto home»